A Dosimetric Analysis of Modified Volumetric Modulated Arc Therapy for Bone Marrow Sparing Radiotherapy in Cervical Cancer-An Alternative Approach to Conventional VMAT

Overview

Journal Asian Pac J Cancer Prev

Specialty Oncology

Date 2022 Dec 29

PMID 36580016

Authors

Dharmendran Palani

Kesavan Govindaraj

Sowmiya Sampathrajan

Lavanya Karunagaran

Kadirampatti M Ganesh

Affiliations

Soon will be listed here.

Abstract

Background: External beam radiotherapy remains the primary treatment modality in cervical cancer. Nowadays Intensity Modulated Radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) are increasingly being used to reduce normal tissue toxicity. The drawback of conventional VMAT is that a considerable volume of pelvic bone marrow receives a low dose.

Aim: We analyzed whether there was a way to reduce the volume of the low dose regions of bone marrow, and assessed the potential benefit of conventional-4Arc (C-4Arc VMAT), and Modified-4Arc (M-4Arc VMAT) over the conventional 2 ARC VMAT.

Materials And Methods: Twelve clinically proven locally advanced cervical cancer patients treated with concurrent chemo-radiotherapy by Conventional VMAT (RapidArc) in dual rotation mode (C-2Arc VMAT) were selected for this study.C-4Arc VMAT and M-4Arc VMAT dose plans were generated for these twelve patients and these three different types of plans were evaluated for the quality and compared dosimetrically.

Results: M-4Arc VMAT designs exhibited a greater bone marrow sparing when compared with conventional VMATs with respect to volume receiving 5Gy to 35Gy without compromising PTV dose coverage. M-4Arc VMAT plans, the bone marrow volume receiving 30 Gy (V30Gy),40Gy (V40Gy), and mean doses were lower than the C- 4 Arc plan and a similar result was observed for V50(Gy) also when comparing with the standard 2 Arc plan. In modified VMAT plans, the rectum and bladder dose volumes were lower than standard VMAT. Similarly, the bowel bag V35(Gy), V40(Gy), V50(Gy), mean doses. The right and left femoral head doses were reduced significantly when compared to conventional VMAT plans.

Conclusion: The M-4Arc VMAT plans are better than the C-2Arc and C-4Arc VMAT plans for reducing the dose to bone marrow by limiting the MLC field width travel.

References

Deng X, Han C, Chen S, Xie C, Yi J, Zhou Y . Dosimetric benefits of intensity-modulated radiotherapy and volumetric-modulated arc therapy in the treatment of postoperative cervical cancer patients. J Appl Clin Med Phys. 2017; 18(1):25-31. PMC: 5689869. DOI: 10.1002/acm2.12003. View

Green J, Kirwan J, Tierney J, Symonds P, Fresco L, Collingwood M . Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001; 358(9284):781-6. DOI: 10.1016/S0140-6736(01)05965-7. View

Peters 3rd W, Liu P, Barrett 2nd R, STOCK R, Monk B, Berek J . Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000; 18(8):1606-13. DOI: 10.1200/JCO.2000.18.8.1606. View

Hui B, Zhang Y, Shi F, Wang J, Wang T, Wang J . Association between bone marrow dosimetric parameters and acute hematologic toxicity in cervical cancer patients undergoing concurrent chemoradiotherapy: comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy. Int J Gynecol Cancer. 2014; 24(9):1648-52. PMC: 4215915. DOI: 10.1097/IGC.0000000000000292. View

Mahantshetty U, Krishnatry R, Chaudhari S, Kanaujia A, Engineer R, Chopra S . Comparison of 2 contouring methods of bone marrow on CT and correlation with hematological toxicities in non-bone marrow-sparing pelvic intensity-modulated radiotherapy with concurrent cisplatin for cervical cancer. Int J Gynecol Cancer. 2012; 22(8):1427-34. DOI: 10.1097/IGC.0b013e3182664b46. View

Guckenberger M, Richter A, Krieger T, Wilbert J, Baier K, Flentje M . Is a single arc sufficient in volumetric-modulated arc therapy (VMAT) for complex-shaped target volumes?. Radiother Oncol. 2009; 93(2):259-65. DOI: 10.1016/j.radonc.2009.08.015. View

Lukovic J, Patil N, DSouza D, Millman B, Yaremko B, Leung E . Intensity-Modulated Radiation Therapy Versus 3D Conformal Radiotherapy for Postoperative Gynecologic Cancer: Are They Covering the Same Planning Target Volume?. Cureus. 2016; 8(1):e467. PMC: 4771573. DOI: 10.7759/cureus.467. View

Lim K, Small Jr W, Portelance L, Creutzberg C, Jurgenliemk-Schulz I, Mundt A . Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer. Int J Radiat Oncol Biol Phys. 2010; 79(2):348-55. DOI: 10.1016/j.ijrobp.2009.10.075. View

Mell L, Kochanski J, Roeske J, Haslam J, Mehta N, Yamada S . Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2006; 66(5):1356-65. DOI: 10.1016/j.ijrobp.2006.03.018. View

10.

Vaupel P, Thews O, Hoeckel M . Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol. 2002; 18(4):243-59. DOI: 10.1385/MO:18:4:243. View

11.

Otto K . Volumetric modulated arc therapy: IMRT in a single gantry arc. Med Phys. 2008; 35(1):310-7. DOI: 10.1118/1.2818738. View

12.

Lukka H, Hirte H, Fyles A, Thomas G, Elit L, Johnston M . Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer--a meta-analysis. Clin Oncol (R Coll Radiol). 2002; 14(3):203-12. DOI: 10.1053/clon.2002.0076. View

13.

Toledano I, Graff P, Serre A, Boisselier P, Bensadoun R, Ortholan C . Intensity-modulated radiotherapy in head and neck cancer: results of the prospective study GORTEC 2004-03. Radiother Oncol. 2012; 103(1):57-62. DOI: 10.1016/j.radonc.2011.12.010. View

14.

Lai Y, Chen Y, Wu S, Shi L, Fu L, Ha H . Modified Volumetric Modulated Arc Therapy in Left Sided Breast Cancer After Radical Mastectomy With Flattening Filter Free Versus Flattened Beams. Medicine (Baltimore). 2016; 95(14):e3295. PMC: 4998812. DOI: 10.1097/MD.0000000000003295. View

15.

Hall E . Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys. 2006; 65(1):1-7. DOI: 10.1016/j.ijrobp.2006.01.027. View

16.

Mell L, Tiryaki H, Ahn K, Mundt A, Roeske J, Aydogan B . Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer. Int J Radiat Oncol Biol Phys. 2008; 71(5):1504-10. DOI: 10.1016/j.ijrobp.2008.04.046. View

17.

Ugurlu B, Temelli O . The impact of the field width on VMAT plan quality and the assessment of half field method. J Appl Clin Med Phys. 2020; 21(3):115-122. PMC: 7075377. DOI: 10.1002/acm2.12834. View

18.

Zelefsky M, Kollmeier M, Cox B, Fidaleo A, Sperling D, Pei X . Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012; 84(1):125-9. DOI: 10.1016/j.ijrobp.2011.11.047. View

19.

Jang H, Park J, Artz M, Zhang Y, Ricci J, Huh S . Effective Organs-at-Risk Dose Sparing in Volumetric Modulated Arc Therapy Using a Half-Beam Technique in Whole Pelvic Irradiation. Front Oncol. 2021; 11:611469. PMC: 8416480. DOI: 10.3389/fonc.2021.611469. View

20.

Morris M, Eifel P, Lu J, Grigsby P, Levenback C, STEVENS R . Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999; 340(15):1137-43. DOI: 10.1056/NEJM199904153401501. View